Trial Profile
A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Certolizumab pegol (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary) ; Triamcinolone (Primary) ; Azathioprine; Corticosteroids; Glucocorticoids; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Prednisolone; Prednisone; Sulfasalazine
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms NORD-STAR
- 15 Nov 2023 Results of post hoc analysis (n=330) presented at the ACR Convergence 2023
- 15 Nov 2023 Results of 48 Week Patient-reported Outcomes , presented at the ACR Convergence 2023
- 15 Nov 2023 Results of a spin-off study from main NORD-STAR study assessing effects of different initial treatments on NET formation in patients with early RA presented at the ACR Convergence 2023